In Braun et al.'s study, mutations in leukemia-related genes including TET2 and ASXL1 did not predict positive response to HMT in chronic myelomonocytic leukemia (CMML), one of the myelodysplastic/myeloproliferative disorders [15]. This evidence concerns the gene TET2 and leukemia.